nodes	percent_of_prediction	percent_of_DWPC	metapath
Phentolamine—ADRA1D—polycystic ovary syndrome	0.353	0.412	CbGaD
Phentolamine—ADRA1B—polycystic ovary syndrome	0.301	0.351	CbGaD
Phentolamine—ADRA1A—polycystic ovary syndrome	0.203	0.237	CbGaD
Phentolamine—Naphazoline—ADRA1A—polycystic ovary syndrome	0.00173	1	CrCbGaD
Phentolamine—NISCH—adrenal cortex—polycystic ovary syndrome	0.00158	0.0629	CbGeAlD
Phentolamine—NISCH—uterus—polycystic ovary syndrome	0.0013	0.0518	CbGeAlD
Phentolamine—NISCH—pituitary gland—polycystic ovary syndrome	0.00127	0.0509	CbGeAlD
Phentolamine—NISCH—adipose tissue—polycystic ovary syndrome	0.00127	0.0507	CbGeAlD
Phentolamine—NISCH—adrenal gland—polycystic ovary syndrome	0.00114	0.0454	CbGeAlD
Phentolamine—NISCH—female gonad—polycystic ovary syndrome	0.00106	0.0424	CbGeAlD
Phentolamine—NISCH—vagina—polycystic ovary syndrome	0.00105	0.0421	CbGeAlD
Phentolamine—SIGMAR1—adrenal cortex—polycystic ovary syndrome	0.000916	0.0366	CbGeAlD
Phentolamine—ADRA1D—endocrine gland—polycystic ovary syndrome	0.000823	0.0329	CbGeAlD
Phentolamine—SIGMAR1—endometrium—polycystic ovary syndrome	0.000818	0.0327	CbGeAlD
Phentolamine—SIGMAR1—uterus—polycystic ovary syndrome	0.000754	0.0301	CbGeAlD
Phentolamine—SIGMAR1—pituitary gland—polycystic ovary syndrome	0.00074	0.0296	CbGeAlD
Phentolamine—SIGMAR1—adipose tissue—polycystic ovary syndrome	0.000737	0.0295	CbGeAlD
Phentolamine—ADRA2C—adrenal cortex—polycystic ovary syndrome	0.00072	0.0288	CbGeAlD
Phentolamine—SIGMAR1—adrenal gland—polycystic ovary syndrome	0.000661	0.0264	CbGeAlD
Phentolamine—ADRA2C—endometrium—polycystic ovary syndrome	0.000643	0.0257	CbGeAlD
Phentolamine—SIGMAR1—female gonad—polycystic ovary syndrome	0.000617	0.0246	CbGeAlD
Phentolamine—SIGMAR1—vagina—polycystic ovary syndrome	0.000613	0.0245	CbGeAlD
Phentolamine—ADRA1A—adipose tissue—polycystic ovary syndrome	0.000608	0.0243	CbGeAlD
Phentolamine—ADRA2C—uterus—polycystic ovary syndrome	0.000592	0.0237	CbGeAlD
Phentolamine—ADRA2C—pituitary gland—polycystic ovary syndrome	0.000581	0.0232	CbGeAlD
Phentolamine—ADRA2C—adipose tissue—polycystic ovary syndrome	0.000579	0.0231	CbGeAlD
Phentolamine—ADRA1A—adrenal gland—polycystic ovary syndrome	0.000545	0.0218	CbGeAlD
Phentolamine—ADRA2C—adrenal gland—polycystic ovary syndrome	0.000519	0.0208	CbGeAlD
Phentolamine—ADRA2A—endometrium—polycystic ovary syndrome	0.000513	0.0205	CbGeAlD
Phentolamine—ADRA2C—female gonad—polycystic ovary syndrome	0.000484	0.0194	CbGeAlD
Phentolamine—ADRA2C—vagina—polycystic ovary syndrome	0.000481	0.0192	CbGeAlD
Phentolamine—ADRA1A—endocrine gland—polycystic ovary syndrome	0.000473	0.0189	CbGeAlD
Phentolamine—ADRA2A—uterus—polycystic ovary syndrome	0.000472	0.0189	CbGeAlD
Phentolamine—ADRA2A—pituitary gland—polycystic ovary syndrome	0.000464	0.0185	CbGeAlD
Phentolamine—ADRA2A—adipose tissue—polycystic ovary syndrome	0.000462	0.0185	CbGeAlD
Phentolamine—ADRA2A—adrenal gland—polycystic ovary syndrome	0.000414	0.0166	CbGeAlD
Phentolamine—ADRA2A—female gonad—polycystic ovary syndrome	0.000386	0.0154	CbGeAlD
Phentolamine—ADRA2A—vagina—polycystic ovary syndrome	0.000384	0.0153	CbGeAlD
Phentolamine—ADRA2A—endocrine gland—polycystic ovary syndrome	0.000359	0.0144	CbGeAlD
Phentolamine—ADRA2A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	1.55e-05	0.000133	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—LHB—polycystic ovary syndrome	1.54e-05	0.000132	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—AKR1C3—polycystic ovary syndrome	1.54e-05	0.000132	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—RBP4—polycystic ovary syndrome	1.54e-05	0.000132	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—YAP1—polycystic ovary syndrome	1.54e-05	0.000132	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—FGF18—polycystic ovary syndrome	1.53e-05	0.000131	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.53e-05	0.000131	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—GAB1—polycystic ovary syndrome	1.52e-05	0.00013	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—CYP17A1—polycystic ovary syndrome	1.52e-05	0.00013	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—GNAS—polycystic ovary syndrome	1.52e-05	0.00013	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—RBP4—polycystic ovary syndrome	1.51e-05	0.00013	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—GNRH1—polycystic ovary syndrome	1.51e-05	0.000129	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ADRA1A—polycystic ovary syndrome	1.51e-05	0.000129	CbGpPWpGaD
Phentolamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	1.51e-05	0.000129	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.5e-05	0.000129	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—SULT2A1—polycystic ovary syndrome	1.5e-05	0.000128	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—GNAS—polycystic ovary syndrome	1.49e-05	0.000128	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PGR—polycystic ovary syndrome	1.49e-05	0.000128	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—FST—polycystic ovary syndrome	1.47e-05	0.000126	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	1.46e-05	0.000125	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	1.46e-05	0.000125	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	1.46e-05	0.000125	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ADRB3—polycystic ovary syndrome	1.45e-05	0.000125	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—INSR—polycystic ovary syndrome	1.45e-05	0.000124	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—RRM2—polycystic ovary syndrome	1.45e-05	0.000124	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—SCT—polycystic ovary syndrome	1.45e-05	0.000124	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—YAP1—polycystic ovary syndrome	1.44e-05	0.000123	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—LHB—polycystic ovary syndrome	1.44e-05	0.000123	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	1.43e-05	0.000123	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—GAB1—polycystic ovary syndrome	1.42e-05	0.000122	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—YAP1—polycystic ovary syndrome	1.41e-05	0.000121	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—GNRH1—polycystic ovary syndrome	1.4e-05	0.00012	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—YAP1—polycystic ovary syndrome	1.4e-05	0.00012	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—GAB1—polycystic ovary syndrome	1.39e-05	0.00012	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—IGF1—polycystic ovary syndrome	1.39e-05	0.000119	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—AKT2—polycystic ovary syndrome	1.39e-05	0.000119	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PLAT—polycystic ovary syndrome	1.38e-05	0.000119	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—GHRL—polycystic ovary syndrome	1.38e-05	0.000119	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	1.38e-05	0.000118	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.38e-05	0.000118	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	1.36e-05	0.000117	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.36e-05	0.000116	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—FGF18—polycystic ovary syndrome	1.36e-05	0.000116	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	1.36e-05	0.000116	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—INSR—polycystic ovary syndrome	1.36e-05	0.000116	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—RBP4—polycystic ovary syndrome	1.35e-05	0.000115	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—SCT—polycystic ovary syndrome	1.34e-05	0.000115	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PGR—polycystic ovary syndrome	1.34e-05	0.000115	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—NAMPT—polycystic ovary syndrome	1.34e-05	0.000115	CbGpPWpGaD
Phentolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	1.34e-05	0.000115	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—INSR—polycystic ovary syndrome	1.33e-05	0.000114	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.33e-05	0.000114	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	1.33e-05	0.000114	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—GNAS—polycystic ovary syndrome	1.33e-05	0.000114	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—CYP11A1—polycystic ovary syndrome	1.32e-05	0.000114	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—ATF1—polycystic ovary syndrome	1.32e-05	0.000113	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—SERPINE1—polycystic ovary syndrome	1.32e-05	0.000113	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—TH—polycystic ovary syndrome	1.31e-05	0.000113	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.29e-05	0.00011	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.29e-05	0.00011	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	1.28e-05	0.00011	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.28e-05	0.00011	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—SLC2A4—polycystic ovary syndrome	1.28e-05	0.000109	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.27e-05	0.000109	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.27e-05	0.000109	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—FGF18—polycystic ovary syndrome	1.26e-05	0.000108	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—YAP1—polycystic ovary syndrome	1.26e-05	0.000108	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PGR—polycystic ovary syndrome	1.25e-05	0.000108	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—AKR1C3—polycystic ovary syndrome	1.25e-05	0.000107	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—RBP4—polycystic ovary syndrome	1.25e-05	0.000107	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PLAT—polycystic ovary syndrome	1.25e-05	0.000107	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—GHRL—polycystic ovary syndrome	1.25e-05	0.000107	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.25e-05	0.000107	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—GAB1—polycystic ovary syndrome	1.24e-05	0.000106	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PGR—polycystic ovary syndrome	1.23e-05	0.000106	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—CYP17A1—polycystic ovary syndrome	1.23e-05	0.000106	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—GNAS—polycystic ovary syndrome	1.23e-05	0.000106	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—NGFR—polycystic ovary syndrome	1.22e-05	0.000104	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—POMC—polycystic ovary syndrome	1.21e-05	0.000104	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PRL—polycystic ovary syndrome	1.21e-05	0.000104	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.2e-05	0.000103	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—CYP19A1—polycystic ovary syndrome	1.2e-05	0.000103	CbGpPWpGaD
Phentolamine—ADRA2B—Hemostasis—VEGFA—polycystic ovary syndrome	1.2e-05	0.000103	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—ATF1—polycystic ovary syndrome	1.19e-05	0.000102	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—INSR—polycystic ovary syndrome	1.18e-05	0.000102	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—YAP1—polycystic ovary syndrome	1.17e-05	0.0001	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PLAT—polycystic ovary syndrome	1.17e-05	0.0001	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—GHRL—polycystic ovary syndrome	1.17e-05	0.0001	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.16e-05	9.98e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.16e-05	9.97e-05	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.16e-05	9.92e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—GAB1—polycystic ovary syndrome	1.15e-05	9.87e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PLAT—polycystic ovary syndrome	1.15e-05	9.85e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—GHRL—polycystic ovary syndrome	1.15e-05	9.85e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.15e-05	9.82e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.13e-05	9.66e-05	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.12e-05	9.64e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Hemostasis—VEGFA—polycystic ovary syndrome	1.12e-05	9.58e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—ATF1—polycystic ovary syndrome	1.11e-05	9.55e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.11e-05	9.5e-05	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.11e-05	9.49e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—INSR—polycystic ovary syndrome	1.1e-05	9.44e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—NGFR—polycystic ovary syndrome	1.1e-05	9.43e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PGR—polycystic ovary syndrome	1.1e-05	9.41e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—ATF1—polycystic ovary syndrome	1.1e-05	9.39e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—POMC—polycystic ovary syndrome	1.09e-05	9.37e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PRL—polycystic ovary syndrome	1.09e-05	9.35e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.09e-05	9.31e-05	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.08e-05	9.27e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—GNAS—polycystic ovary syndrome	1.07e-05	9.18e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.07e-05	9.16e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—TH—polycystic ovary syndrome	1.07e-05	9.14e-05	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.06e-05	9.12e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—GNAS—polycystic ovary syndrome	1.06e-05	9.11e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.05e-05	9.01e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.05e-05	8.97e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—SLC2A4—polycystic ovary syndrome	1.04e-05	8.89e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.03e-05	8.87e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.03e-05	8.83e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—NGFR—polycystic ovary syndrome	1.03e-05	8.81e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—POMC—polycystic ovary syndrome	1.02e-05	8.75e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—NCOR1—polycystic ovary syndrome	1.02e-05	8.75e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—GHRL—polycystic ovary syndrome	1.02e-05	8.75e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PLAT—polycystic ovary syndrome	1.02e-05	8.75e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PGR—polycystic ovary syndrome	1.02e-05	8.74e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PRL—polycystic ovary syndrome	1.02e-05	8.73e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.01e-05	8.68e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—NGFR—polycystic ovary syndrome	1.01e-05	8.67e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—POMC—polycystic ovary syndrome	1e-05	8.62e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PRL—polycystic ovary syndrome	1e-05	8.59e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—NRG1—polycystic ovary syndrome	9.93e-06	8.52e-05	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—POMC—polycystic ovary syndrome	9.82e-06	8.43e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—AKT2—polycystic ovary syndrome	9.81e-06	8.41e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—CYP19A1—polycystic ovary syndrome	9.74e-06	8.36e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—ATF1—polycystic ovary syndrome	9.73e-06	8.34e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—CYP1A1—polycystic ovary syndrome	9.67e-06	8.29e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—ADRB2—polycystic ovary syndrome	9.66e-06	8.28e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—AKT2—polycystic ovary syndrome	9.65e-06	8.28e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—GNAS—polycystic ovary syndrome	9.59e-06	8.22e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—ADRB2—polycystic ovary syndrome	9.5e-06	8.15e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	9.49e-06	8.14e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PLAT—polycystic ovary syndrome	9.48e-06	8.13e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—GHRL—polycystic ovary syndrome	9.48e-06	8.13e-05	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	9.44e-06	8.1e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—NCOR1—polycystic ovary syndrome	9.13e-06	7.83e-05	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	9.13e-06	7.83e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—VEGFA—polycystic ovary syndrome	9.07e-06	7.78e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ATF1—polycystic ovary syndrome	9.04e-06	7.75e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—MTHFR—polycystic ovary syndrome	9.02e-06	7.73e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—NGFR—polycystic ovary syndrome	8.98e-06	7.7e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—NRG1—polycystic ovary syndrome	8.96e-06	7.69e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—GNAS—polycystic ovary syndrome	8.95e-06	7.68e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—POMC—polycystic ovary syndrome	8.92e-06	7.65e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PRL—polycystic ovary syndrome	8.9e-06	7.63e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	8.82e-06	7.56e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—GNAS—polycystic ovary syndrome	8.81e-06	7.56e-05	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	8.77e-06	7.53e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—GNAS—polycystic ovary syndrome	8.7e-06	7.46e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—AKT2—polycystic ovary syndrome	8.58e-06	7.36e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.53e-06	7.32e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IRS2—polycystic ovary syndrome	8.5e-06	7.29e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	8.44e-06	7.24e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.39e-06	7.2e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—NRG1—polycystic ovary syndrome	8.37e-06	7.18e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NGFR—polycystic ovary syndrome	8.34e-06	7.16e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—LEP—polycystic ovary syndrome	8.32e-06	7.14e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—POMC—polycystic ovary syndrome	8.29e-06	7.11e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—NCOR1—polycystic ovary syndrome	8.29e-06	7.11e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PRL—polycystic ovary syndrome	8.27e-06	7.09e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—NRG1—polycystic ovary syndrome	8.24e-06	7.07e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	7.97e-06	6.83e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	7.85e-06	6.74e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	7.84e-06	6.73e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—GNAS—polycystic ovary syndrome	7.83e-06	6.71e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IRS2—polycystic ovary syndrome	7.68e-06	6.59e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—LEP—polycystic ovary syndrome	7.51e-06	6.44e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	7.46e-06	6.4e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IRS1—polycystic ovary syndrome	7.42e-06	6.37e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	7.32e-06	6.28e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—NRG1—polycystic ovary syndrome	7.32e-06	6.28e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PPARG—polycystic ovary syndrome	7.31e-06	6.27e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	7.27e-06	6.24e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—POMC—polycystic ovary syndrome	7.21e-06	6.18e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IRS2—polycystic ovary syndrome	7.17e-06	6.15e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—INS—polycystic ovary syndrome	7.17e-06	6.15e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—POMC—polycystic ovary syndrome	7.15e-06	6.13e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—INS—polycystic ovary syndrome	7.11e-06	6.1e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IRS2—polycystic ovary syndrome	7.06e-06	6.05e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—LEP—polycystic ovary syndrome	7.02e-06	6.02e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.93e-06	5.94e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—LEP—polycystic ovary syndrome	6.91e-06	5.92e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IGF1—polycystic ovary syndrome	6.88e-06	5.9e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—AKT2—polycystic ovary syndrome	6.87e-06	5.89e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	6.8e-06	5.83e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IRS1—polycystic ovary syndrome	6.7e-06	5.75e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.53e-06	5.6e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—POMC—polycystic ovary syndrome	6.45e-06	5.54e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—INS—polycystic ovary syndrome	6.42e-06	5.51e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IRS2—polycystic ovary syndrome	6.27e-06	5.38e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IRS1—polycystic ovary syndrome	6.26e-06	5.37e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IGF1—polycystic ovary syndrome	6.21e-06	5.33e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—AKT2—polycystic ovary syndrome	6.2e-06	5.32e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IRS1—polycystic ovary syndrome	6.16e-06	5.29e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—LEP—polycystic ovary syndrome	6.13e-06	5.26e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—POMC—polycystic ovary syndrome	6.03e-06	5.17e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—INS—polycystic ovary syndrome	6e-06	5.14e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	5.94e-06	5.09e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—POMC—polycystic ovary syndrome	5.93e-06	5.09e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—INS—polycystic ovary syndrome	5.9e-06	5.06e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.9e-06	5.06e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	5.86e-06	5.02e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	5.82e-06	5e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—INS—polycystic ovary syndrome	5.82e-06	5e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IGF1—polycystic ovary syndrome	5.8e-06	4.97e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—AKT2—polycystic ovary syndrome	5.79e-06	4.97e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IGF1—polycystic ovary syndrome	5.71e-06	4.9e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—AKT2—polycystic ovary syndrome	5.7e-06	4.89e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	5.7e-06	4.89e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.51e-06	4.72e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IRS1—polycystic ovary syndrome	5.47e-06	4.69e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.42e-06	4.65e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—POMC—polycystic ovary syndrome	5.27e-06	4.52e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—IL6—polycystic ovary syndrome	5.26e-06	4.51e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—INS—polycystic ovary syndrome	5.24e-06	4.5e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	5.09e-06	4.36e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IGF1—polycystic ovary syndrome	5.07e-06	4.35e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AKT2—polycystic ovary syndrome	5.07e-06	4.35e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	4.9e-06	4.2e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	4.87e-06	4.18e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.81e-06	4.13e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—IL6—polycystic ovary syndrome	4.75e-06	4.07e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	4.71e-06	4.04e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	4.71e-06	4.04e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.49e-06	3.85e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.47e-06	3.84e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—IL6—polycystic ovary syndrome	4.43e-06	3.8e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—IL6—polycystic ovary syndrome	4.36e-06	3.74e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.05e-06	3.48e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—IL6—polycystic ovary syndrome	3.88e-06	3.33e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.79e-06	3.25e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.73e-06	3.2e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	3.6e-06	3.09e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.31e-06	2.84e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IL6—polycystic ovary syndrome	3.11e-06	2.66e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.08e-06	2.64e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IL6—polycystic ovary syndrome	2.8e-06	2.41e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IL6—polycystic ovary syndrome	2.62e-06	2.25e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IL6—polycystic ovary syndrome	2.58e-06	2.21e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IL6—polycystic ovary syndrome	2.29e-06	1.96e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	2.13e-06	1.83e-05	CbGpPWpGaD
